Mr. Speaker, this week Mississauga has once again been the target of massive investment in research and development.
Astra AB, the parent company of Mississauga East based Astra Pharma, has launched the development of a revolutionary new treatment for osteoporosis. In a new partnership with Allelix Biopharmaceuticals, also of Mississauga, Astra will provide Allelix with $50 million in licensing and development funds to move this new product forward aggressively.
I congratulate Astra Pharma and Allelix for bringing $50 million worth of jobs and investment to Mississauga and offering relief to the world's 200 million sufferers of osteoporosis.